# Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers

> **NCT00512538** · PHASE3 · TERMINATED · sponsor: **Organogenesis** · enrollment: 82 (actual)

## Conditions studied

- Diabetic Foot

## Interventions

- **DEVICE:** Bi-layered cell therapy (Apligraf)

## Key facts

- **NCT ID:** NCT00512538
- **Lead sponsor:** Organogenesis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-10
- **Primary completion:** —
- **Final completion:** 2002-09
- **Target enrollment:** 82 (ACTUAL)
- **Why stopped:** Interruption of business relations between Study Sponsor and Device Manufacturer
- **Last updated:** 2007-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00512538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00512538, "Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00512538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*